The September 1, 2022, article by Provencio et al entitled “Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)” (J Clin Oncol 10.1200/JCO.21.02660) was published with an error.
The first sentence of the caption for Figure 3 read as: Kaplan-Meier curves for (A) PFS and (B) OS according to ctDNA detection after neoadjuvant treatment and Kaplan-Meier curves for (C) PFS and (D) OS by clinical response assessed on CT scans (landmark approach).
It should have read as: Kaplan-Meier curves for (A) PFS and (B) OS by clinical response assessed on CT scans and Kaplan-Meier curves for (C) PFS and (D) OS according to ctDNA detection after neoadjuvant treatment (landmark approach).
This has been corrected as of September 28, 2022. The authors apologize for the error.